Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, Conference Calls/ Webcasts

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit


VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Jefferies Inaugural Biotech CNS/Neuro Summit to be held on October 11, 2023.

Company Fireside Chat Presentation Details:

Date:Wednesday, October 11, 2023
  
Time:2:25 PM Eastern Time
  
Webcast:Register here
  
Presenters:Ian Mortimer, President and Chief Executive Officer
Sherry Aulin, Chief Financial Officer
  

A live webcast of the company presentation will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: (604) 484-3353
Email: [email protected]



These press releases may also interest you

at 16:20
TOP-RANKED HEALTHCARE CONSULTING FIRM EXPANDS ROSTER, DEEPENS LEADERSHIP
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...

at 16:10
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...

at 16:10
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of...

at 16:05
Anna Richo joins Illumina's Board of Directors
Illumina, Inc. announced today that Anna Richo has joined the company's Board of Directors following shareholder approval of the director slate at the company's May 16, 2024, annual meeting. Ms. Richo currently serves as Corporate Senior Vice...

at 16:05
PELOTON INTERACTIVE, INC. ANNOUNCES LAUNCH OF GLOBAL REFINANCING
Peloton Interactive, Inc. ("Peloton") today announced that it intends to launch a global refinancing, pursuant to which it will offer $275.0 million aggregate principal amount of convertible senior notes due 2029 (the "notes") in a private offering...

at 15:52
WHISTLEBLOWER ALLEGES GLAXOSMITHKLINE LIED ABOUT ZANTAC SAFETY CLAIMS
Valisure LLC, a technology company that conducts independent chemical analysis of pharmaceuticals, filed an amended complaint in a recently...

More news about Health...


News published on and distributed by: